The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-"The rotation is much more than newsflow on a vaccine"

Thu, 19th Nov 2020 10:23

* European shares fall led by oil, banks

* Rising U.S. virus cases and lockdowns sour mood

* STOXX down 0.9% after late Wall Street sell-off

* U.S. stock index futures inch lower
Welcome to the home for real-time coverage of markets brought to
you by Reuters reporters. You can share your thoughts with us at
markets.research@thomsonreuters.com

"THE ROTATION IS MUCH MORE THAN NEWSFLOW ON A VACCINE" (1112
GMT)

There is no trace this morning in Europe of the rotation
trade that has made this November so special.

The debate, however, about whether the shift from growth
into value has legs, goes on.

JP Morgan quants have weighed in and their main point is
that the move is much more than a reaction to positive vaccine
news, which provided a powerful catalyst last week.

"We believe the rotation towards Value and out of Quality is
much more than newsflow on a vaccine," strategists at the U.S.
investment bank say, pointing to the very positive trend in
earnings upgrades currently underway.

"Historically, this backdrop has been support to both
Cyclicals and Value stocks," they add.

That said, one may wonder where are the opportunities from
the trend in earnings expectations? Here's their response.

1) The price of Value needs to play catch-up to the sharp
improvement in the earnings trend for Value stocks

2) The upgrades for Staples, Discretionary, Technology and
Health Care are now posting the smallest improvements inEPS
revisions; their data is peaking or is already slowing.

3) The three sectors switches that follow these trends
include: long Financials/short Staples; long Industrials/short
Healthcare; long Energy/short Technology

(Danilo Masoni)

*****

EUROPE AT THE OPEN: ROTATION DARLINGS GET HIT (0830 GMT)

Europe is playing catch up with a late sell-off on Wall
Street, as rising COVID-19 cases and lockdowns in the U.S. are
triggering a broad risk off move.

Those sectors that were favoured during this month's strong
rotation are hit the most this morning as the focus returns to
the pandemic's near term damage to the economy and profits.

Oil, banks, miners, travel and leisure stocks are the top
sectoral fallers in early deals, while healthcare, tech and
defensive utilities are managing to limit losses.

There are some bright spots however. Royal Mail shares are
rising 6% to the top of the STOXX with some analysts flagging an
improved revenue outlook.

Underscoring the damage from the coronavirus crisis is
German conglomerate Thyssenkrupp which said it would need to cut
5,000 more jobs as its latest set of results disappointed. Its
shares are down 6%.

(Danilo Masoni)

*****

On the corporate front there are no major market moving
updates but newsflow continues to show how the coronavirus
crisis is hitting businesses hard, even though not all earning
updates are gloomy as online orders and the stay-at-home economy
grows.

Ailing conglomerate Thyssenkrupp said it needs a
further 5,000 jobs to ease the impact of the COVID-19 crisis,
while budget airline Norwegian Air has asked an Irish
court to oversee a restructuring of its massive debt as it seeks
to stave off collapse.

Meantime the FT has reported that Cineworld is
looking at an insolvency process used to cut costs, as part of
its talks with lenders to gain access to capital.

On a more brighter note, French conglomerate Bouygues
has raised its outlook for the second half of the year
on the back of a strong Q3.

British home improvement retailer Kingfisher saw a
17% jump in quarterly underlying sales, continuing to benefit
from the popularity of do-it-yourself during the pandemic.

More online orders helped Naked Wines raise its
full-year sales forecast as H1 revenues grew nearly 80%
, while online shopping helped Royal Mail
boost sales but losses in its letters unit and virus-related
costs led to a slump in pre-tax profit.

Online trading platform CMC Markets posted a record
net operating income as the coronavirus crisis lifted volatility
in financial markets.

Chemicals maker Johnson Matthey reported a slump in
half-year profit and stayed away from providing an outlook for
2021, as the pandemic continued to dent demand.

In M&A, Swiss engineer ABB unveiled plans to
offload three business units that generate $1.75 billion in
sales.

While we're still waiting for AstraZeneca's late
stage trial results, vaccine developments continue to inspire
confidence following the Pfizer and Moderna updates.

Pfizer and BioNTech could secure
emergency U.S. and European authorization for their COVID-19
vaccine next month with first deliveries possibly before
Christmas.

(Danilo Masoni)

*****

EUROPE SEEN LOWER ON WALL STREET SLIDE (0636 GMT)

European shares could fall sharply at the open today on the
back of heavy late-session losses on Wall Street overnight as
growing COVID-19 infections and shutdowns in the world's largest
economy sour investor sentiment.

The S&P 500 closed down more than 1% yesterday as
losses accelerated after markets here in Europe closed.

The U.S. death toll from COVID-19 surpassed a grim new
milestone of 250,000 lives lost, while NY Fed's Williams said
the rapid increase in infections could hurt the economy, even
though vaccine developments made him "somewhat more optimistic".

While U.S. stock index futures are now steady after
the sell-off, early indications from European futures
point to declines of nearly 1%.

(Danilo Masoni)

*****

More News
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.